ArticleJournal of thoracic disease2019
Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for esophageal squamous cell cancer patients presenting with oligometastases.
Article in Journal of thoracic disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Neutrophil-to-lymphocyte ratio in unresectable or metastatic esophageal squamous cell carcinoma: a systematic review, meta-analysis and meta-regression.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Pooled it
- A meta-analysis of published data on the efficacy and safety of radiotherapy combined with systemic therapy in advanced esophageal carcinoma.Frontiers in oncology · 2026Pooled it
- Role of Local Treatment for Oligometastasis: A Comparability-Based Meta-Analysis.Cancer research and treatment · 2022Pooled it
- Toripalimab plus chemotherapy and radiotherapy for treatment-naive advanced esophageal squamous cell carcinoma: a single-arm phase 2 trial.Nature communications · 2024Trial
- Prognostic analysis and treatment utilization of different treatment strategies in elderly esophageal cancer patients with distant metastases: a SEER database analysis.Journal of cancer research and clinical oncology · 2023Trial
- Efficacy and safety of radiotherapy plus immunochemotherapy in patients with oligometastatic esophageal cancer.Future oncology (London, England) · 2026Article
- Efficacy comparison of first-line treatment regimens for stage IV esophageal squamous cell carcinoma with supraclavicular lymph node metastasis: A study of the oligometastatic subtype.Therapeutic advances in medical oncology · 2026Article
- Efficacy and safety of radiotherapy combined with chemoimmunotherapy versus chemoimmunotherapy alone as first-line treatment for metachronous oligorecurrent esophageal squamous cell carcinoma.Frontiers in oncology · 2026Article
- Article
- Radiotherapy combined with chemoimmunotherapy improves survival compared to chemoimmunotherapy alone as first-line treatment for oligometastatic esophageal squamous cell carcinoma.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025Article
- The role of radiotherapy in small cell carcinoma of the esophagus: a retrospective study.Radiation oncology (London, England) · 2025Article
- Oligometastatic disease - a renaissance for surgery?Innovative surgical sciences · 2025Review
- Improving the efficacy of late-line immunotherapy for advanced esophageal cancer: the addition of local radiotherapy.Therapeutic advances in gastroenterology · 2025Article
- Comparative Analysis of Concurrent Chemoradiotherapy Versus Chemotherapy Alone as First-Line Palliative Treatments for Advanced Esophageal Squamous Cell Carcinoma.Journal of clinical medicine · 2024Article
- [Gender medicine in diseases of the upper gastrointestinal tract].Chirurgie (Heidelberg, Germany) · 2024Review
- Effects of Local Treatment in Combination with Systemic Therapy for Advanced Esophageal Cancer: A Systematic Review and Meta-analysis.Advances in radiation oncology · 2024Review
- Review
- Article
- Evaluation of Concurrent Chemoradiotherapy for Survival Outcomes in Patients With Synchronous Oligometastatic Esophageal Squamous Cell Carcinoma.JAMA network open · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 4 countries.
Funding
Abstract
backgroundThe potential survival benefits of adding radiotherapy to systemic therapy for esophageal cancer patients with oligometastases are unknown.
methodsIn this retrospective analysis, patients with stage IV esophageal cancer (according to the American Joint Committee on Cancer Seventh edition staging system) with ≤3 metastases who underwent chemotherapy with cisplatin/paclitaxel between 2012 and 2015 were identified. Patients received chemotherapy (CT) alone
resultsOf 461 patients, 97% had squamous cell cancer. One hundred and ninety-six patients (42.5%) received CCRT and 265 (57.5%) underwent CT alone. At week 8, there were 3 (1.5%) complete responses (CR) and 95 (48.5%) partial responses (PR) in the CCRT group, compared to 3 (1.1%) CR and 102 (38.5%) PR in the CT alone group. The overall rate of improvement in dysphagia score was noted in 78.5% of patients in the CCRT group versus 61.5% in the CT alone group (P=0.014). A statistically significant difference was demonstrated in disease control rate between the two groups (81.6%
conclusionsCompared to chemotherapy alone, chemoradiation to all sites in patients with esophageal cancer with ≤3 metastases may lead to a modest increase in PFS and a trend toward longer OS. Further investigation of optimal integration of radiotherapy and chemotherapy in these patients is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.